Michel Delforge speaks to Roshaine Gunawardana, Managing Commissioning Editor: Michel Delforge is a senior clinical investigator and Professor of Medicine at the Department of Hematology of the Catholic University, Leuven, Belgium. He was trained in Leuven and at the University of Minnesota, MN, USA, and obtained a doctoral degree in biomedical sciences. He is Clinical Head and directs the myeloma and myelodysplasia clinic of the Department of Hematology at University Hospital Leuven. Delforge is a member of the Executive Committee of the Stem Cell Institute Leuven and holds a hematology chair of the central fractionation unit of the Belgian Red Cross. He is an active member of the Belgian Myeloma Working Party, Intergroupe Francophone du Myélome (IFM), Dutch–Belgian Cooperative Trail Group for Hematological Oncology (HOVON) and International Myeloma Working Party (IMWG). His topics of interest include the side effects and management of new drugs in myeloma, translational research in myeloma and myelodysplastic syndromes.